You are here:

infliximab 100mg powder for intravenous infusion (Remicade)

Advice

following a full submission:

 
infliximab (Remicade®) is not recommended for use within NHS Scotland for maintenance treatment of fistulising, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). Infliximab was not approved by NICE in 2002 for patients with fistulating Crohn’s disease who do not have the other criteria for severe active Crohn’s disease.
 
Infliximab maintenance treatment, compared to placebo, was associated with a longer time to loss of fistula response in patients with fistulising Crohn’s disease. The manufacturer’s justification of the treatment cost in relation to its health benefits was not sufficient to gain acceptance by SMC.

Drug Details

Drug Name: infliximab 100mg powder for intravenous infusion (Remicade)
SMC Drug ID: 364/07
Manufacturer: Schering-Plough Ltd
Indication: for the treatment of fistulising, active Crohn's disease.
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Superseded
Date Advice Published: 6 May 2007

Back